Skip to main content

Advertisement

Table 3 Mean bids across treatment groups

From: The impact of free trial acceptance on demand for alternative nicotine products: evidence from experimental auctions

  Overalla (N = 258) Control (N = 62) Snus trial (N = 64) Nicorette trial (N = 67) Ariva trial (N = 65)
Bid Snus US$1.00 US$0.72 US$0.60 US$1.55b US$1.13
(1.86) (1.12) (0.98) (1.53) (1.90)
Bid Nicorette US$1.87 US$2.04 US$1.54 US$1.87 US$2.03
(2.62) (2.23) (2.23) (3.13) (2.78)
Bid Ariva US$1.40 US$1.44 US$0.91 US$1.78 US$1.47
(1.92) (1.42) (1.42) (2.11) (2.42)
Bid Cigarettes US$4.06 US$4.09 US$3.30 US$4.16 US$4.76
(2.34) (1.84) (1.89) (4.09) (2.44)
  1. (Standard deviations in parentheses)
  2. Difference in bids for those who tried snus vs. those who chose not to try snus is statistically significant at the 5 % level
  3. aDifferences in bids across all four products are statistically significant at the 5 % level using a 2-sided t test
  4. bDifferences in bids for snus in the group that received the snus trial and those that received the Nicorette trial are statistically significant at the 5 % level using a 2-sided t test